Genentech Announces Interim Results from Phase III HAVEN 2 Study
On April 16, 2017 Genentech announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII. According to this Genentech’s press releases, “interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically meaningful reduction in the number of bleeds over time.”
Read Genentech’s full press release regarding this data in it’s entirety.
Assisting and Advocating for the Bleeding Disorders Community